Article

New PCSK9 Approval, Biosimilar Cost Tops Specialty Pharmacy Week in Review

Author(s):

Davy James, Managing Editor

Top stories of the week on Specialty Pharmacy Times.

[<a href="//storify.com/pharmacytimes/pcsk9-approval-biosimilar-cost" target="_blank">View the story "New PCSK9 Approval, Biosimilar Cost Tops Specialty Pharmacy Week in Review" on Storify</a>]

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com
Related Content
Kidneys affected by chronic kidney disease (CKD) -- Image credit: Crystal light | stock.adobe.com
June 17th 2025

Multi-Phenotype Approach Highlights Increased Power of cPCA When Identifying CKD-Related Loci

Gillian McGovern, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Patient with plaque psoriasis -- Image credit: fusssergei | stock.adobe.com
June 16th 2025

FDA Approves Ustekinumab-Stba, Biosimilar to Stelara, for Pediatric Patients With PsO or PsA

Gillian McGovern, Associate Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Editor
The Evolving Role of the Pharmacist in HEOR: Bridging Clinical and Economic Evidence
June 13th 2025

The Evolving Role of the Pharmacist in HEOR: Bridging Clinical and Economic Evidence

Muhammad Cheema, PharmD, MPBA
Chronic kidney disease (CKD) -- Image credit: Kiattisak | stock.adobe.com
June 12th 2025

Finerenone and Empagliflozin Outperform Either Treatment Alone in Patients With CKD

Gillian McGovern, Associate Editor